-99.6%
DFNS vs MRNA
+945.0%
-1,044.7%
-99.7%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -18.3% | +13.1% | -31.4% | -18.8% |
| 7D | -27.7% | +20.6% | -48.3% | -28.3% |
| 30D | -58.0% | +27.1% | -85.1% | -58.5% |
| 3M | -94.0% | +353.4% | -447.4% | -94.6% |
| 6M | -94.6% | +446.3% | -540.8% | -94.7% |
| YTD | -99.4% | +776.2% | -875.6% | -99.4% |
| 1Y | -99.6% | +987.9% | -1,087.6% | -99.6% |
| All | -99.6% | +945.0% | -1,044.7% | -99.6% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling